Taivex Therapeutics Corporation logo

Taivex Therapeutics Corporation

Taivex has proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions. Hec1 was found to be over-expressed in many cancer cells, and the phosphorylation of Hec1 by Nek2 is critical for proper mitotic progress and chromosome segregation. Interruption of Hec1-Nek2 interaction results in mitotic defects, which lead to cell death. Hec1-Nek2 interactions regulate key events in the progression of human tumors, and therefore are attractive molecule targets for the development of new anti-cancer drugs.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.taivex.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2F, NO. 12, Dongxing Rd., Songshan Dist.
Taipei 105
Taiwan
Email
Contact Number
+886 2 2655 8300

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/taivex-therapeutics” connections=”true” suffix=””]